These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26087135)

  • 21. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
    O'Malley PG
    Arch Intern Med; 2012 Jul; 172(13):1014-5. PubMed ID: 22688778
    [No Abstract]   [Full Text] [Related]  

  • 22. Updates on the Clinical Trials in Diabetic Macular Edema.
    Demirel S; Argo C; Agarwal A; Parriott J; Sepah YJ; Do DV; Nguyen QD
    Middle East Afr J Ophthalmol; 2016; 23(1):3-12. PubMed ID: 26957834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How to manage patients with center-involving diabetic macular edema and good visual acuity? An answer to a common clinical question.
    Moisseiev E; Loewenstein A
    Eye (Lond); 2019 Nov; 33(11):1677-1678. PubMed ID: 31471564
    [No Abstract]   [Full Text] [Related]  

  • 24. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
    Jampol LM; Glassman AR; Liu D; Aiello LP; Bressler NM; Duh EJ; Quaggin S; Wells JA; Wykoff CC;
    Ophthalmology; 2018 Jul; 125(7):1054-1063. PubMed ID: 29525602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema.
    Konidaris VE; Tsaousis KT; Al-Hubeshy Z; Pieri K; Deane J; Empeslidis T
    Eye (Lond); 2017 Nov; 31(11):1629-1630. PubMed ID: 28622326
    [No Abstract]   [Full Text] [Related]  

  • 26. A Comparison Study of Ranibizumab and Aflibercept in Patients with Naive Diabetic Macular Edema in Presence of Serous Retinal Detachment.
    Kaldırım H; Yazgan S; Kırgız A; Atalay K; Savur F
    Curr Eye Res; 2019 Sep; 44(9):987-993. PubMed ID: 30983426
    [No Abstract]   [Full Text] [Related]  

  • 27. Determinants in Initial Treatment Choice for Diabetic Macular Edema.
    VanderBeek BL; Scavelli K; Yu Y
    Ophthalmol Retina; 2020 Jan; 4(1):41-48. PubMed ID: 31345726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
    Glassman AR; Liu D; Jampol LM; Sun JK;
    Invest Ophthalmol Vis Sci; 2018 Mar; 59(3):1199-1205. PubMed ID: 29625440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data.
    Holekamp N; Duff SB; Rajput Y; Garmo V
    J Med Econ; 2020 Mar; 23(3):287-296. PubMed ID: 31502893
    [No Abstract]   [Full Text] [Related]  

  • 30. New Findings From Diabetic Retinopathy Clinical Research Retina Network Protocol V Confirm a Role for Focal Laser Photocoagulation or Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: New Is Not Always Best.
    Peto T; Chakravarthy U
    JAMA Ophthalmol; 2019 Jul; 137(7):838-839. PubMed ID: 31037285
    [No Abstract]   [Full Text] [Related]  

  • 31. Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial.
    Bressler SB; Odia I; Maguire MG; Dhoot DS; Glassman AR; Jampol LM; Marcus DM; Solomon SD; Sun JK;
    JAMA Ophthalmol; 2019 Apr; 137(4):382-389. PubMed ID: 30676635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ziv-aflibercept in macular disease.
    Mansour AM; Al-Ghadban SI; Yunis MH; El-Sabban ME
    Br J Ophthalmol; 2015 Aug; 99(8):1055-9. PubMed ID: 25677668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Short-term Effect of a Single Lapse in Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema Within Routine Clinical Practice.
    Yalamanchili SP; Maatouk CM; Enwere DU; Conti TF; Hom GL; Briskin IN; Greenlee TE; Babiuch AS; Singh RP
    Am J Ophthalmol; 2020 Nov; 219():215-221. PubMed ID: 32640254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry.
    Bhandari S; Nguyen V; Fraser-Bell S; Mehta H; Viola F; Baudin F; Gabrielle PH; Creuzot-Garcher C; Gillies M; Barthelmes D
    Ophthalmology; 2020 May; 127(5):608-615. PubMed ID: 31932092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes.
    Ciulla TA; Pollack JS; Williams DF
    Br J Ophthalmol; 2021 Feb; 105(2):216-221. PubMed ID: 32265201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Individualized treat-and-extend regime for optimization of real-world vision outcome and improved patients' persistence.
    Volkmann I; Knoll K; Wiezorrek M; Greb O; Framme C
    BMC Ophthalmol; 2020 Mar; 20(1):122. PubMed ID: 32228517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective.
    van Asten F; Michels CTJ; Hoyng CB; van der Wilt GJ; Klevering BJ; Rovers MM; Grutters JPC
    PLoS One; 2018; 13(5):e0197670. PubMed ID: 29772018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
    Ross EL; Hutton DW; Stein JD; Bressler NM; Jampol LM; Glassman AR;
    JAMA Ophthalmol; 2016 Aug; 134(8):888-96. PubMed ID: 27280850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Higher priced drugs are not cost effective for diabetic macular edema, US study finds.
    McCarthy M
    BMJ; 2016 Jun; 353():i3253. PubMed ID: 27283845
    [No Abstract]   [Full Text] [Related]  

  • 40. Three-month outcomes of ziv-aflibercept in the treatment of diabetic macular oedema.
    Ashraf M; Souka AA; El Kayal H; El Manhaly M; Abdallah MH
    Acta Ophthalmol; 2016 Nov; 94(7):e669. PubMed ID: 27227354
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.